Weight Loss Drugs Like Ozempic Offer Temporary Benefits, Study Finds
A new study reveals that the meaningful weight loss achieved through medications like Ozempic, Wegovy, and Mounjaro is frequently enough not sustained once patients discontinue use, underscoring the need for comprehensive long-term support.
Recent scientific research conducted at the University of Oxford and published in The BMJ analyzed data from 37 previous studies, encompassing a total of 9,341 participants, to determine the lasting effects of glucagon-like peptide-1 (GLP-1) receptor agonists – a class of drugs initially developed for diabetes management. These medications, which work by mimicking a hormone that regulates appetite and cravings, have gained widespread popularity as a weight loss solution, even among individuals without diabetes.
The study’s findings indicate that individuals who stop taking these weight management medications typically regain their original weight within an average of 1.7 years. Researchers observed a weight regain rate of approximately 0.4 kilograms (0.88 pounds) per month,a pace roughly four times faster than that seen in individuals who achieve weight loss through behavioral programs focused on diet and physical activity.
“These medicines are transforming obesity treatment and can achieve crucial weight loss,” explained Dr. Sam West of the Nuffield Department of Primary Care Health sciences at the University of Oxford, in a statement to The Guardian. “However, our research shows that people tend to regain weight rapidly after stopping – faster than we see with behavioral programmes. This isn’t a failing of the medicines – it reflects the nature of obesity as a chronic, relapsing condition. It sounds a cautionary note for short-term use without a more comprehensive approach to long-term weight management, and highlights the importance of primary prevention.”
The research also revealed a concerning trend: the reduced risk of obesity-related health conditions,such as high blood pressure and elevated cholesterol,also reverted to pre-treatment levels within 1.4 years of stopping the medications.
According to the study’s authors, “WMMs are associated with a reduction in weight and improvements in cardiometabolic health that are attenuated soon after treatment ends, with no evidence of benefit 1.7 years after the cessation of treatment. This evidence cautions against short-term use of WMMs, emphasises the need for further research into cost-effective strategies for long-term weight control, and reinforces the importance of primary prevention.”
Unlike medications for conditions like high cholesterol, which are often prescribed for indefinite use, most weight loss drugs are not intended for long-term treatment. Consequently,many patients eventually discontinue their medication,potentially facing weight regain without ongoing medical or nutritional guidance. The study suggests that combining these drugs with comprehensive behavioral programs could yield more enduring results.
The findings emphasize that accomplished weight management requires a holistic approach, extending beyond pharmaceutical intervention to include sustained lifestyle changes and ongoing support.
here’s a breakdown answering the “5 Ws and H”:
* Who: Researchers at the University of Oxford conducted the study, analyzing data from 9,341 participants across 37 previous studies. Dr.Sam West of the University of Oxford provided a statement.
* What: The study found that weight loss achieved through medications like Ozempic, Wegovy, and Mounjaro (GLP-1 receptor agonists) is often temporary, with individuals regaining weight and losing cardiometabolic benefits within 1.7 years of stopping the drugs.
* Why: The weight regain occurs because these medications are not typically prescribed for long-term use, and obesity is a chronic, relapsing condition. The study highlights the need for a more
